We are a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. Our strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that we believe have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.
Market Cap | 597.309 Million | Shares Outstanding | 44.609 Million | Avg 30-day Volume | 511.769 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.36 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -185.014 Million |
Price to Book Value | 1.1198 | Operating Margin | 0.0 | Enterprise Value | 60.609 Million |
Current Ratio | 18.677 | EPS Growth | 0.232 | Quick Ratio | 18.245 |
1 Yr BETA | 1.7869 | 52-week High/Low | 30.33 / 7.3 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -142.9431 | Altman Z-Score | 14.4999 | Free Cash Flow to Firm | -85.112 Million |
Earnings Report | 2022-08-09 |
Please sign in first
1.9 Million total shares from 9 transactions
520.6 Thousand total shares from 7 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
16,475 | 2022-06-22 | 10 | |
|
16,475 | 2022-06-22 | 2 | |
|
16,475 | 2022-06-22 | 2 | |
|
16,475 | 2022-06-22 | 2 | |
|
4,430,964 | 2022-06-21 | 4 | |
AHMED NADIM PRESIDENT AND CEO |
|
8,090 | 2022-06-06 | 4 |
BIOTECHNOLOGY VALUE FUND II LP |
|
7,415,823 | 2022-06-01 | 4 |
|
4,532,867 | 2022-05-12 | 4 | |
|
0 | 2022-03-01 | 2 | |
JONES JEFFREY ALAN CHIEF MEDICAL OFFICER |
|
0 | 2022-02-28 | 2 |
BAEUERLE PATRICK SEE REMARKS |
|
453,934 | 2022-02-11 | 3 |
KEANE RAYMOND T CHIEF LEGAL OFFICER |
|
69,124 | 2022-02-11 | 1 |
ZAWEL LEIGH SEE REMARKS |
|
134,785 | 2022-02-11 | 9 |
SAVILL CORRINE ACTING CHIEF BUSINESS OFFICER |
|
242,615 | 2022-02-11 | 1 |
MICHAELSON JENNIFER CHIEF DEVELOPMENT OFFICER |
|
108,411 | 2022-02-11 | 5 |
TRIGILIO JEFFREY CHIEF FINANCIAL OFFICER |
|
114,750 | 2022-02-11 | 3 |
|
7,800 | 2021-09-16 | 4 | |
|
7,648,268 | 2021-09-16 | 8 | |
ONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P. |
|
7,805,483 | 2021-08-23 | 8 |
|
6,139,339 | 2021-01-12 | 4 | |
HUGHES OWEN PRESIDENT AND CEO |
|
506,226 | 2021-01-12 | 0 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 22:15:03 UTC | 0.5497 | 1.0203 | 550000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 21:45:03 UTC | 0.5497 | 1.0203 | 550000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 21:15:04 UTC | 0.5497 | 1.0203 | 550000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 20:45:03 UTC | 0.5279 | 1.0421 | 550000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 20:15:03 UTC | 0.5279 | 1.0421 | 550000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 19:45:03 UTC | 0.5279 | 1.0421 | 550000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 19:15:03 UTC | 0.5279 | 1.0421 | 550000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 18:45:03 UTC | 0.3051 | 1.2649 | 550000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 18:15:04 UTC | 0.3051 | 1.2649 | 550000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 17:45:03 UTC | 0.3051 | 1.2649 | 550000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 17:15:03 UTC | 0.3051 | 1.2649 | 550000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 16:45:03 UTC | 0.2876 | 1.2824 | 550000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 16:15:03 UTC | 0.2876 | 1.2824 | 550000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 15:45:03 UTC | 0.2876 | 1.2824 | 7000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 15:15:03 UTC | 0.2876 | 1.2824 | 10000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 14:45:03 UTC | 0.5434 | 1.0266 | 10000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 14:15:03 UTC | 0.5434 | 1.0266 | 10000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 13:45:03 UTC | 0.5434 | 1.0266 | 10000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 13:15:03 UTC | 0.5434 | 1.0266 | 10000 |
CULLINAN ONCOLOGY INC CGEM | 2022-06-24 12:45:03 UTC | 0.5434 | 1.0266 | 10000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | CGEM | -1200.0 shares, $-12564.0 | 2022-03-31 | N-PORT |